Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study

OBJECTIVE: To evaluate survival following afatinib (AF) and erlotinib (ER) treatment in advanced del19 lung adenocarcinoma (AD19LA) with asymptomatic brain metastasis (ABM) after pemetrexed–cisplatin chemotherapy (PCC). METHODS: Data were retrospectively analysed from individuals with AD19LA and ABM...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Ye, Chen, Wenli, Yu, Weiguang, Shi, Ning, Han, Guowei, Mao, Shuai, Zhang, Xinlei, Chen, Meiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Retrospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432978/
https://www.ncbi.nlm.nih.gov/pubmed/32804557
http://dx.doi.org/10.1177/0300060520937093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432978/
https://www.ncbi.nlm.nih.gov/pubmed/32804557
http://dx.doi.org/10.1177/0300060520937093

Ejemplares similares